Infinity shares battered over safety jitters

Shares of Infinity Pharmaceuticals ($INFI) took a beating on Monday, as investors reacted to some of the new safety data that the company reported on its PI3K delta/gamma inhibitor IPI-145 at ASCO. And even though shares regained some of that value on Tuesday, it's still far, far off the $50.09 52-week high recorded in early April. Infinity was reporting early-stage data on the drug, which has captured the attention of many in the biotech community. Story